Category Archives: US pressure on India
Prices of patented drugs are lower in Canada, United Kingdom and Australia in comparison to the US By Aneesh Phadnis & Reuters| Published: Business Standard | february 1, 2017 Indian pharma industry is fearing a tougher US government stance on intellectual … Continue reading
In a review submitted to USTR, four US industry bodies have said that India has developed a “positive” approach over the compulsory licensing issue. Written by Liz Mathew, The Indian Express | New Delhi | March 8, 2016 The US-India … Continue reading
A bilateral investment pact would be beneficial to both India and the US: USIBC President Nayanima Basu, The Hindu BusinessLine|February 17, 2016 Mukesh Aghi, President, US-India Business Council (USIBC), said although India has given verbal assurance on not issuing compulsory … Continue reading
PhRMA Special 301 Submission 2016 insists that India remains on the Priority Watch List in the USTR Special 301 Report. PhRMA sees India’s progressive Patent Act of 2005 and IP environment as a legal and regulatory barrier to patentability of … Continue reading
The Sun Daily; November 16, 2015. Kuala Lumpur – US president Barack Obama will be among the big names who will be here this week to attend the 27th annual Asean meeting between Nov 18 and 22. Other leaders who have confirmed attendance … Continue reading
The Wire; November 2, 2015. By Priti Patnaik. The United States and Switzerland want the right to file complaints for loss of trade ‘benefits’ even against countries whose intellectual property rights laws are fully consistent with international agreements.